Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Acta Oto-Laryngologica

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/00016480802590451PMID 19863327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2011cited by this paper
• Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)

  2007cited by this paper
• Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

  2006cited by this paper
• Microvessel Density in Head and Neck Squamous Cell Carcinoma Primary Tumors and Its Correlation with Clinical Staging Parameters

  2006cited by this paper
• A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

  2005cited by this paper
• Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.

  2005cited by this paper
• Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.

  2005cited by this paper
• Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

  2004cited by this paper
• Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?

  2004cited by this paper
• Weekly Paclitaxel and Carboplatin Combination Chemotherapy in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck

  2003cited by this paper
• Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

  2003cited by this paper
• Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma

  2002cited by this paper
• Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

  2002cited by this paper
• Antiangiogenic scheduling of lower dose cancer chemotherapy.

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck

  1998cited by this paper
• Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial.

  1993cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Multi-agent chemotherapy for refractory head and neck cancer

  2026cites this paper
• Efficacy of oral metronomic chemotherapy in the management of head and neck squamous cell carcinoma—a systematic review

  2025cites this paper
• NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.

  2025cites this paper
• Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study

  2025influential citation
• Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer.

  2025cites this paper
• Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma

  2025cites this paper
• Treatment of recurrent and/or metastatic disease

  2024cites this paper
• Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma

  2024cites this paper
• Long-Term Survival after Stereotactic Radiotherapy Combined with Immunotherapy in a Patient with Recurrent Oral Cancer

  2024cites this paper
• Pembrolizumab in treatment of head and neck squamous cell carcinoma: clinical cases and real-world practice

  2023cites this paper
• Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients

  2022cites this paper
• Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients

  2022cites this paper
• Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

  2022cites this paper
• Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center

  2022cites this paper
• Oral metronomic therapy in head and neck cancer.

  2021cites this paper
• Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.

  2021cites this paper
• Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pre-treated recurrent and metastatic head and neck cancer.

  2021cites this paper
• Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab

  2021cites this paper
• Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME

  2021cites this paper
• Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

  2021cites this paper
• Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.

  2019cites this paper
• Novel immune‐modulating drugs for advanced head and neck cancer

  2019cites this paper
• Chemotherapy for Oral Cancer.

  2018cites this paper
• Specific skin changes induced by chemotherapy

  2018cites this paper
• Informe de Posicionamiento Terapéutico de nivolumab (Opdivo®) en el tratamiento de cáncer de cabeza y cuello

  2018cites this paper
• NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

  2018cites this paper
• AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma

  2018cites this paper
• Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.

  2018cites this paper
• Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.

  2018cites this paper
• NCCN Guidelines ® Insights Head and Neck Cancers , Version 1 . 2018 Featured Updates to the NCCN Guidelines

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

  2017cites this paper
• Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03

  2017cites this paper
• Cancers de la sphère ORL: l’immunothérapie donne de la voix !

  2017cites this paper
• Potential for low-value palliative care of patients with recurrent head and neck cancer.

  2017cites this paper
• Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer

  2017cites this paper
• Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors

  2017cites this paper
• A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.

  2017cites this paper
• Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

  2017cites this paper
• Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer: ―個別化最大継続可能量設定を目的とした開始用量決定のための第1相試験―

  2016cites this paper
• Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  2016cites this paper
• Cancer and orofacial pain

  2016cites this paper
• Metronomic Chemotherapy for Advanced Pleomorphic Adenocarcinoma of the Nasopharynx

  2016cites this paper
• Chemotherapy in Head and Neck Squamous Cell Cancer

  2016cites this paper
• Metronomic chemotherapy for advanced pleomorphic adenocarcinoma of the nasopharynx.

  2016cites this paper
• A genetic view of laryngeal cancer heterogeneity

  2016cites this paper
• Development of LC–MS method for analysis of paclitaxel-inhibited growth and enhanced therapeutic response in human glioblastoma cells

  2015cites this paper
• Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck

  2015cites this paper
• Head and Neck Cancers, Version 2.2014

  2014cites this paper
• Introducción de Cetuximab en el tratamiento del carcinoma escamoso de cabeza y cuello

  2014cites this paper
• Outcome of patients treated with palliative weekly Paclitaxel plus Cetuximab in recurrent head and neck cancer after failure of platinum-based therapy

  2014cites this paper
• Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

  2014cites this paper
• An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

  2014cites this paper
• Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform.

  2014cites this paper
• The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.

  2014cites this paper
• Kutanes Plattenepithelkarzinom unter Berücksichtigung besonderer Patientengruppen

  2014cites this paper
• [Management of adverse events due to antineoplastic agents].

  2013cites this paper
• Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial.

  2013cites this paper
• Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone

  2013cites this paper
• Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy

  2012cites this paper
• Oropharynx cancer.

  2012cites this paper
• Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

  2012cites this paper
• Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer

  2011influential citation
• Current chemotherapies for recurrent/metastatic head and neck cancer

  2011cites this paper
• Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck

  2011cites this paper
• Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2011cites this paper
• Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution

  2010cites this paper
• Optimal treatment for recurrent/metastatic head and neck cancer.

  2010cites this paper
• Advances in the systemic treatment of head and neck cancers

  2010cites this paper
• Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel.

  2009cites this paper
• World Journal of Clinical Oncology

  year unknowninfluential citation
• Original Articles Annals of Oncology

  year unknowncites this paper
• Head and Neck Cancers, Version 2.2025 Featured Updates to the NCCN Guidelines

  year unknowncites this paper